🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07042984
Starting soon Observational

RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer

NCT07042984 · tracked via the Priya Life Science China tracker
Sponsor
Fujian Medical University
Phase
Observational
Started
2025-07-01
Last updated
2025-06-29

Condition(s) studied

Papillary Thyroid CarcinomaThyroid NeoplasmsRET Proto-Oncogene MutationLymphatic Metastasis

Investigational drug(s) / intervention(s)

AI-Ultrasound RET Prediction

AI-Ultrasound RET Prediction: Deep-learning algorithm that analyses thyroid ultrasound DICOM images and outputs a probability score for RET gene alteration and lateral-neck lymph-node metastasis; run offline, results blinded to treating surgeons.

Study summary

Why is this study being done? RET gene alterations occur in only 5-10 % of papillary thyroid cancers, but they can change how surgeons treat the disease. Gene testing is costly and not always performed, so many RET-positive tumours are missed. Researchers have built a computer program (artificial-intelligence or "AI" model) that reads routine thyroid ultrasound images and predicts whether the tumour carries a RET alteration and whether the cancer has already spread to lymph-nodes in the side of the neck.

What will happen in this study?

About 800 adults who are scheduled for thyroid-cancer surgery will take part. Each participant will:

* have a standard pre-operative ultrasound exam (no extra scanning time),
* give a routine fine-needle sample for a 14-gene panel test (results in 24 h), and
* allow the AI model to analyse the ultrasound images in the background. Doctors making treatment decisions will not see the AI result. After surgery, the research team will compare the AI predictions with the gene-panel result and the final pathology report.

Main goal: To find out how accurately the AI model detects RET alterations. Secondary goals: To measure the model's ability to predict lymph-node spread, and to compare costs between ultrasound-only prediction and full gene testing.

Benefits and risks: Participants will receive the current standard of care; there is no added risk beyond the usual ultrasound and needle biopsy. The study could lead to faster, less expensive ways to identify high-risk thyroid cancers in the future.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Age 18-75 years, able to provide written informed consent. * Pre-operative ultrasound findings highly suggestive of papillary thyroid carcinoma. * Planned thyroidectomy (any extent) at a participating institution. * Willing to undergo rapid 11-gene next-generation sequencing (NGS) panel and allow use of ultrasound DICOM images for AI analysis. Exclusion Criteria: * Prior thyroid or major neck surgery. * Known medullary thyroid carcinoma, anaplastic carcinoma, or metastatic disease outside the neck. * Multiple endocrine neoplasia (MEN) syndromes or clinical suspicion of multi-gland disease. * Pregnant or breastfeeding. * Severe renal impairment (eGFR \< 30 mL/min/1.73 m²) or other condition that precludes surgery or gene testing.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fujian Medical University Union Hospital Fuzhou FJ

More Fujian Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07042984 on ClinicalTrials.gov ↗ ← All trials in China